

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 November 2024 (07.11.2024)



(10) International Publication Number
WO 2024/228132 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 513/02 (2006.01)
C07D 413/14 (2006.01) A61P 29/00 (2006.01)
C07D 417/14 (2006.01) A61P 35/00 (2006.01)
C07D 498/04 (2006.01) A61K 31/428 (2006.01)

(21) International Application Number:

PCT/IB2024/054242

(22) International Filing Date:

02 May 2024 (02.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202341031205 02 May 2023 (02.05.2023) IN
202341084043 09 December 2023 (09.12.2023) IN

(71) Applicant: AURIGENE ONCOLOGY LIMITED

[IN/IN]; 39/40(P), KIADB Industrial Area, Electronics City
Phase II, Bangalore, Karnataka, Bangalore 560 100 (IN).

(72) Inventors: ABBINENI, Chandrasekhar; Plot#387, IKI-

GAI, Journalists' colony phase 3, Gopanpally, Telangana,
Hyderabad 500032 (IN). SAMAJDAR, Susanta; R801,
HM Tambourine, JP Nagar 6th Phase, Karnataka, Bangalore
560078 (IN). TALLURI, Krishna Chaitanya; Flat No.
401, Srinadha Nilayam, opp. ALIND Employees colony,
park, Sudarshan Nagar, Lingampally, Telangana, Hyder-
abad 500019 (IN). MUKHERJEE, Subhendu; B208, SLV
Sankalpa, Naganathapura, Central Jail Road, Karnataka,
Bangalore 560100 (IN). MIDUTURU, Chandrasekhar V;
134 Vassal Ln, Cambridge, Massachusetts 02138 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS



(57) Abstract: The present disclosure provides fused bicyclic heterocyclyl compounds and their derivatives of formula (I), which are therapeutically useful as CCR4 modulators. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the modulation of CCR4 activity. Compounds of the present disclosure are especially useful for treating cancer and inflammatory diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

WO 2024/228132 A1